- Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION)
-
Lee BW, Min K, Hong EG, Ku BJ, Kang JG, Chon S, Lee WY, Park MK, Kim JH, Kim SY, Song K, Yoo SJ
- KMID: 2543319
- Endocrinol Metab.
- 2023 Jun;38(3):328-337.
- doi: 10.3803/EnM.2023.1688
Background: This study evaluated the efficacy and safety of add-on gemigliptin in patients with type 2 diabetes mellitus (T2DM) who had inadequate glycemic control with metformin and dapagliflozin. Methods: In this... -
- CITED
-
- Close
- SHARE
-
- Close
- Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
-
Lin TY, Kang EYC, Shao SC, Lai ECC, Garg SJ, Chen KJ, Kang JH, Wu WC, Lai CC, Hwang YS
- KMID: 2542516
- Diabetes Metab J.
- 2023 May;47(3):394-404.
- doi: 10.4093/dmj.2022.0221
Background: To compare risk of diabetic retinopathy (DR) between patients taking sodium-glucose cotransporter-2 inhibitors (SGLT2is) and those taking glucagon-like peptide-1 receptor agonists (GLP1-RAs) in routine care. Methods: This retrospective cohort study... -
- CITED
-
- Close
- SHARE
-
- Close
- SGLT2 Inhibitors: Emerging Drugs in Heart Failure
-
Cho DH
- KMID: 2541451
- Korean J Med.
- 2023 Apr;98(2):59-63.
- doi: 10.3904/kjm.2023.98.2.59
Sodium-glucose cotransporter 2 (SGLT2) inhibitors constitute a class of diabetes medications that have demonstrated the potential to improve outcomes for heart failure (HF) patients. Although they were originally developed to... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance
-
Moon JS, Kim NH, Na JO, Cho JH, Jeong IK, Lee SH, Mok JO, Kim NH, Chung DJ, Cho J, Lee DW, Lee SW, Won KC
- KMID: 2538933
- Diabetes Metab J.
- 2023 Jan;47(1):82-91.
- doi: 10.4093/dmj.2021.0356
Background: To evaluate the safety and effectiveness of empagliflozin in routine clinical settings, we collected and assessed the clinical profiles of Korean patients with type 2 diabetes mellitus. Methods: This was... -
- CITED
-
- Close
- SHARE
-
- Close
- Common ABCB1 SNP, C3435T could affect systemic exposure of dapagliflozin in healthy subject
-
Hwang JG, Jeong SI, Kim YK, Lee Y, Ji SC, Lee S, Park MK
- KMID: 2538883
- Transl Clin Pharmacol.
- 2022 Dec;30(4):212-225.
- doi: 10.12793/tcp.2022.30.e23
P-glycoprotein (P-gp) is a transporter that plays an excretory role in epithelial cells. It is encoded by ABCB1, and single nucleotide polymorphisms (SNPs) in this gene can affect systemic drug... -
- CITED
-
- Close
- SHARE
-
- Close
- Dietary Changes Leading to Euglycemic Diabetic Ketoacidosis in Sodium-Glucose Cotransporter-2 Inhibitor Users: A Challenge for Primary Care Physicians?
-
Somagutta MKR, Uday U, Shama N, Bathula NR, Pendyala S, Mahadevaiah A, Mahmutaj G, Ngardig NN
- KMID: 2536174
- Korean J Fam Med.
- 2022 Nov;43(6):361-366.
- doi: 10.4082/kjfm.22.0003
Background: The use of euglycemic diabetic ketoacidosis (EDKA) related to sodium-glucose cotransporter 2 inhibitors (SGLT2i) use in people with diabetes has been increasingly reported. The causes are multifactorial, and dietary... -
- CITED
-
- Close
- SHARE
-
- Close
- Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors
-
Chan ATP, Tang SCW
- KMID: 2540197
- Kidney Res Clin Pract.
- 2022 Nov;41(6):682-698.
- doi: 10.23876/j.krcp.21.285
Progress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis). Although sodium-glucose co-transporter 2 inhibitors (SGLT2is) have revolutionized the... -
- CITED
-
- Close
- SHARE
-
- Close
- Diabetic kidney disease treatment: new perspectives
-
Tong LL, Adler SG
- KMID: 2535413
- Kidney Res Clin Pract.
- 2022 Sep;41(Suppl 2):S63-S73.
- doi: 10.23876/j.krcp.21.288
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease and end-stage kidney disease worldwide, as the obesity epidemic and the burden of diabetes continue to rise globally.... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice
-
Seo DH, Suh YJ, Cho Y, Ahn SH, Seo S, Hong S, Lee Yh, Choi YJ, Lee E, Kim SH
- KMID: 2532717
- Yonsei Med J.
- 2022 Sep;63(9):825-833.
- doi: 10.3349/ymj.2022.63.9.825
Purpose: This study aimed to evaluate the efficacy and tolerability of dapagliflozin as an add-on or a switch therapy to lobeglitazone plus metformin (MFM) in Korean patients with inadequately controlled... -
- CITED
-
- Close
- SHARE
-
- Close
- Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease
-
Baek JH, Yang YS, Ko SH, Han KD, Kim JH, Moon MK, Park JS, Lee BW, Oh TJ, Chon S, Choi JH, Hur KY, Committee of Clinical Practice Guidelines, Korean Diabetes Association
- KMID: 2533639
- Diabetes Metab J.
- 2022 Sep;46(5):701-712.
- doi: 10.4093/dmj.2022.0002
Background: To evaluate prescription trends and clinical factors of the sodium-glucose cotransporter 2 inhibitors (SGLT2i) use according to the presence of atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF) in... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of the addition of thiazolidinedione to sodium-glucose cotransporter 2 inhibitor therapy on lipid levels in type 2 diabetes mellitus: a retrospective study using Korean National Health Insurance Service data
-
Park T, Han K, Shin D, Park J
- KMID: 2532277
- Cardiovasc Prev Pharmacother.
- 2022 Jul;4(3):114-122.
- doi: 10.36011/cpp.2022.4.e15
Background: Dyslipidemia is common in patients with type 2 diabetes mellitus (T2D) and contributes to an increased risk of cardiovascular disease. Previous studies have shown that treatment with thiazolidinediones (TZDs)... -
- CITED
-
- Close
- SHARE
-
- Close
- Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics
-
Kim NH, Kim NH
- KMID: 2531958
- Diabetes Metab J.
- 2022 Jul;46(4):543-551.
- doi: 10.4093/dmj.2022.0209
Diabetic kidney disease (DKD) is a prevalent renal complication of diabetes mellitus that ultimately develops into end-stage kidney disease (ESKD) when not managed appropriately. Substantial risk of ESKD remains even... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus
-
Lee SE, Nam H, Choi HS, Kim H, Kyoung DS, Kim KA
- KMID: 2531961
- Diabetes Metab J.
- 2022 Jul;46(4):567-577.
- doi: 10.4093/dmj.2021.0160
Background: Although cardiovascular outcome trials using sodium-glucose cotransporter-2 inhibitors (SGLT-2i) showed a reduction in risk of 3-point major adverse cardiovascular events (MACE), they did not demonstrate beneficial effects on stroke... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study
-
Kim HS, Yoon T, Jung CH, Park JY, Lee WJ
- KMID: 2531969
- Diabetes Metab J.
- 2022 Jul;46(4):658-662.
- doi: 10.4093/dmj.2021.0232
Sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) are novel anti-diabetic drugs whose glucose-lowering effect and cardiovascular and renal benefits were evidenced in clinical trials. We investigated... -
- CITED
-
- Close
- SHARE
-
- Close
- Sodium-Glucose Cotransporter-2 Inhibitor-Related Diabetic Ketoacidosis: Accuracy Verification of Operational Definition
-
Kang DY, Kim H, Ko S, Kim H, Shinn J, Kang MG, Byeon Sj, Choi JH, Shin SY, Kim HS
- KMID: 2526516
- J Korean Med Sci.
- 2022 Feb;37(7):e53.
- doi: 10.3346/jkms.2022.37.e53
Background: The most important aspect of a retrospective cohort study is the operational definition (OP) of the disease. We developed a detailed OP for the detection of sodiumglucose cotransporter-2 inhibitors... -
- CITED
-
- Close
- SHARE
-
- Close
- SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
-
Saucedo-Orozco H, Voorrips SN, Yurista SR, de Boer RA, Westenbrink BD
- KMID: 2525232
- J Lipid Atheroscler.
- 2022 Jan;11(1):1-19.
- doi: 10.12997/jla.2022.11.1.1
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as powerful drugs that can be used to treat heart failure (HF) patients, both with preserved and reduced ejection fraction and in the presence... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Weight Reduction in Overweight and Obese Populations without Diabetes: A Systematic Review and a Meta-Analysis
-
Cho YK, Kim YJ, Jung CH
- KMID: 2524573
- J Obes Metab Syndr.
- 2021 Dec;30(4):336-344.
- doi: 10.7570/jomes21061
Background: We aimed to evaluate the efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors for managing obesity in non-diabetic overweight or obese patients. Methods: For purposes of this study, PubMed, Embase, Web... -
- CITED
-
- Close
- SHARE
-
- Close
- Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway
-
Lee JY, Lee M, Lee JY, Bae J, Shin E, Lee Yh, Lee BW, Kang ES, Cha BS
- KMID: 2522731
- Diabetes Metab J.
- 2021 Nov;45(6):921-932.
- doi: 10.4093/dmj.2020.0187
Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new class of antidiabetic drugs that exhibit multiple extraglycemic effects. However, there are conflicting results regarding the effects of SGLT2 inhibition on... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of the Effects of Various Antidiabetic Medication on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus
-
Ha J, Lim Y, Kim MK, Kwon HS, Song KH, Ko SH, Kang MI, Moon SD, Baek KH
- KMID: 2519677
- Endocrinol Metab.
- 2021 Aug;36(4):895-903.
- doi: 10.3803/EnM.2021.1026
Background: Prospective comparative studies on the effects of various antidiabetic agents on bone metabolism are limited. This study aimed to assess changes in bone mass and biochemical bone markers in... -
- CITED
-
- Close
- SHARE
-
- Close
- Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus
-
Jeon JY, Ha KH, Kim DJ
- KMID: 2518893
- Diabetes Metab J.
- 2021 Jul;45(4):505-514.
- doi: 10.4093/dmj.2020.0057
Background: Using real-world data, cardiovascular safety was investigated in metformin users newly starting sodium glucose cotransporter 2 (SGLT2) inhibitors compared with other glucose-lowering drugs in Korea. Methods: This was a retrospective... -
- CITED
-
- Close
- SHARE
-
- Close
